Accelerated Approval Pathway for ALS Drug, Copay Accumulators Under Review
Rich Brennan, Vice President of Federal Affairs for the ALS Association, explains the approval pathway for Tofersen, a new ALS drug, and what that means for patients; Peter Pitts, President and co-founder of the Center for Medicine in the Public...
Rich Brennan, Vice President of Federal Affairs for the ALS Association, explains the approval pathway for Tofersen, a new ALS drug, and what that means for patients; Peter Pitts, President and co-founder of the Center for Medicine in the Public Interest, discusses how this FDA review process evaluates rare disease treatments; the House Health subcommittee discusses copay accumulators and PBMs in hearing; patient correspondent Larry Falivena shares his experience living with ALS and calls for more research funding.
Rich Brennan- Vice President of Federal Affairs for the ALS Association
US FDA panel backs accelerated approval for Biogen's ALS drug
Patients Rising Now Letter FDA Advisory Council
Peter Pitts- President and co-founder of the Center for Medicine in the Public Interest
Health Hearing: “Lowering Unaffordable Costs: Examining Transparency and Competition in Health Care” - (3:15:50)
Darla S. Bell- Copay Accumulator Adjustment Programs: Anti-Patient Practice
Sarah Page- MS, American v Argentinan health care, and great family support
Larry Falivena (Constituent, NC CD-14)
Peter Pitts
Co-Founder and President, Center for Medicine in the Public Interest
Co-Founder and President, Center for Medicine in the Public Interest
Former FDA Associate Commissioner
Listen On
